post myocardial infarction clinical trials results

any anticoagulant versus aspirin
EPSIM, 1982
anticoagulant
versus
aspirin 500mg three times daily
patients surviving myocardial infarctionopen
Follow-up duration: 29 months (range 6-59)
any anticoagulant versus placebo
Sixty Plus reinfarction Study, 1980
anticoagulant
versus
placebo
over 60 years of agedouble blind
Follow-up duration: 2 years
aspirin versus placebo
CDPA, 1976
Aspirin (324 mg) 3x/d
versus
Placebo
MI survivorsDouble blind
Follow-up duration: 1.83 y
USA
Cardiff I, 1974
Aspirin (300 mg) 1x/d
versus
Placebo
MI survivorsDouble blind
Follow-up duration: 2 years
UK
Cardiff II, 1979
Aspirin (300 mg) 3x/d for one year
versus
Placebo
patients with myocardial infarctionDouble blind
Follow-up duration: 1 y
South Wales
Vogel, 1979
Aspirin (1.5 g daily) on an average period of 22 months
versus
Placebo
Double blind
Follow-up duration: 1.75 y (mean)
Germany
AMIS, 1980
NCT00000491
Aspirin (500 mg) 2x/d for at least 3 years
versus
Placebo
men and women who had had a documented myocardial infarctionDouble blind
Follow-up duration: > 3 y
USA
GAMIS, 1980
Aspirin (500 mg) 3x/d for 2 years
versus
Placebo
patients who had survived a myocardial infarction for 30-42 days Double blind
Follow-up duration: 2 y
Germany, Austria,
PARIS, 1980
Aspirin (324 mg) 3x/d
versus
Placebo
patients who had recovered from myocardial infarction Double blind
Follow-up duration: 41 mo
USA, UK
JAMIS, 1999
Aspirin (81 mg) 1x/d
versus
No antiplatelets
patients with AMI within 1 month from the onset of symptomsOpen
Follow-up duration: 1.3 y (mean)
Japan
atorvastatin high dose versus atorvastatin
TNT, 2005
NCT00327691
80 mg of atorvastatin daily
versus
10 mg of atorvastatin daily
Chronic coronary artery disease LDL cholesterol < 3.4 mmol/Ldouble blind
Follow-up duration: 4.9 years
14 countries
atorvastatin high dose versus lovastatin
Vascular basis, 2005
atorvastatin (80 mg) with or without vitamin C and E
versus
low dose lovastatin (5 mg)
Chronic coronary artery diseasedouble blind
Follow-up duration: 1 year
atorvastatin high dose versus pravastatin
REVERSAL, 2004
atorvastatin 80 mg daily
versus
Pravastatin(40 mg)
Chronic coronary artery diseasedouble blind
Follow-up duration: 1.5 years
SAGE, 2007
atorvastatin 80 mg daily
versus
pravastatin(40 mg)
Chronic coronary artery diseasedouble blind
Follow-up duration: 1 years
atorvastatin high dose versus simvastatin
IDEAL, 2005
NCT00159835
atorvastatin 80mg daily
versus
simvastatine 20mg/j
Men and women aged 80 years or younger with a history of a definite myocardial infarction and who qualified for statin therapy according to national guidelinesopen
Follow-up duration: 4.8 years
Denmark, Finland, Iceland, Netherlands, Norway, Sweden
azimilide versus placebo
ALIVE, 2004
azimilide 100 mg
versus
placebo
post-MI patients with depressed LVFdouble blind
Follow-up duration: 1y
bezafibrate versus placebo
BECAIT, 1996
bezafibrate 200 mg three times daily
versus
placebo
dyslipidaemic male survivors of myocardial infarction who were younger than 45 years at the time of the eventdouble blind
Follow-up duration: 5.0 years
Sweden
BIP, 2000
bezafibrate 400 mg/d
versus
placebo
patients with a previous myocardial infarction or stable angina, total cholesterol of 180 to 250 mg/dL, HDL-C < or =45 mg/dL, triglycerides < or =300 mg/dL, and low-density lipoprotein cholesterol < or =180 mg/dL double blind
Follow-up duration: 6.2 y
Israel
canakinumab versus placebo
CANTOS, 2017
NCT01327846
Quarterly Subcutaneous Canakinumab 50mg, 150mg, 300mg for 36 months
versus
placebo
Stable Post-myocardial Infarction Patients With Elevated hsCRPdouble-blind
Follow-up duration: 36 months
class I drugs versus control
BASIS, 1990
individualized antiarrhythmic treatment
versus
no antiarrhythmic therapy
patients with persisting asymptomatic complex arrhythmias after myocardial infarctionopen
Follow-up duration: 1 year
clofibtate+niacin versus placebo
Carlson (Stockholm), 1977
clofibrate, 1 g twice daily, and nicotinic acid 1 g three times daily
versus
control
survivors of a myocardial infarction below 70 years of age open
Follow-up duration: 5 years
Sweden
clopidogrel versus aspirin
CAPRIE, 1996
Clopidogrel (75 mg) 1x/d for a minimum of one year and a maximum of 3 years
versus
Aspirin (325 mg) 1x/d
patients with atherosclerotic vascular disease manifested as either recent ischaemic stroke, recent myocardial infarction, or symptomatic peripheral arterial diseaseDouble blind
Follow-up duration: 1.91 y
16 countries (USA, Canada, Europe, Australia and NZ
coumadin versus aspirin
ASPECT-2 (coumadin alone), 2002
coumadin (phenprocoumon or acenocoumarol) target INR 3-4
versus
aspirin 80mg daily
Acute MI, unstable anginaopen
Follow-up duration: 1 year (range 0-26 months)
the Netherlands
coumadin versus control (on top of aspirin)
ASPECT-2 (coumadin+ASA vs ASA), 2002
coumadin(INR mean 2.4) +aspirin
versus
aspirin
Acute MI, unstable angina open
Follow-up duration: 1 year
the Netherlands
coumadin versus placebo
ASPECT, 1994
nicoumalone or phenprocoumon, target INR 2.8–4.8
versus
placebo
hospital survivors of myocardial infarctiondouble blind
Follow-up duration: 37 months (range 6-76)
d,l sotalol versus placebo
Julian, 1982
sotalol 320 mg once daily
versus
placebo
surviving an acute myocardial infarctiondouble blind
Follow-up duration: 1 year
dabigatran versus placebo
REDEEM, 2009
NCT00621855
dabigatran 4 dosages (50mg twice daily, 75mg twice daily, 110mg twice daily, 150mg twice daily)
versus
placebo
patients with recent acute coronary syndromes (ST- or non-ST-elevation myocardical infarction)double blind
Follow-up duration: 6 months
diltiazem versus placebo
MDPIT, 1988
Diltiazem 60mgx4
versus
placebo
Patient aged 25 to 75 years, admitted to coronary care units with a documented acute myocardial infarctionDouble blind
Follow-up duration: 25 months (at least 12 months)
US, Canada
dipyridamol + aspirin versus aspirin
PARIS, 1980
Aspirin (324 mg) + dipyridamole (75 mg) 3x/d
versus
Aspirin (324 mg) 3x/d
patuents who had recovered from myocardial infarction Double blind
Follow-up duration: 41 months
USA and GB
dipyridamol + aspirin versus placebo
PARIS, 1980
Aspirin (324 mg) + dipyridamole (75 mg) 3x/d
versus
Placebo
patients who had recovered from myocardial infarction Double blind
Follow-up duration: 41 months (mean)
USA and UK
PARIS-II, 1986
Aspirin (330 mg) + dipyridamole (75 mg) 3x/d
versus
Placebo
patients who had recovered from myocardial infarction, suffered from 4 weeks to 4 months previouslyDouble blind
Follow-up duration: 23.4 months
USA and UK
dofetilide versus placebo
DIAMOND MI, 1997
dofetilide
versus
placebo
patients with acute myocardial infarction within 7 days and left ventricular systolic dysfunction (EF <= 35%) double blind
Follow-up duration: >12 months
Danish
early amiodarone versus control
BASIS, 1990
amiodarone 1 g for 5 d; then 200 mg/d started within 4 weeks of AMI
versus
no amiodarone (usual care)
patients with persisting asymptomatic complex arrhythmias after myocardial infarction (Lown class 3 or 4b in > 2 of 24 h)open
Follow-up duration: 12 mo
Navarro-Lopez, 1993
amiodarone 600 mg/d for 1 week, 400 mg/d for 1 week then 200 mg/d started 10-30 d after AMI
versus
no amiodarone
patients who have had MI with a left ventricular ejection fraction of 20 to 45% and > or = 3 ventricular premature complexes per hour (pairs or runs) - 3 VPOs/h, pairs or runs of VTopen
Follow-up duration: 24 mo
Spain
early amiodarone versus placebo
CAMIAT , 1991
amiodarone 10 mg/kg per d for 3 weeks then 300-400 mg/d started 6-45 d after AMI
versus
placebo
patients with acute myocardial infarction within the previous 6-30 days and > 10 VPDs/h for 18 h or a run of VTdouble blind
Follow-up duration: 24 mo
Ceremuzynski, 1992
amiodarone 800 mg/d for 1 week then 200-400 mg/d started 5-7 d after AMI
versus
placebo
No need for antiarrhythmic therapydouble blind
Follow-up duration: 12 mo
Hockings, 1987
amiodarone 200 mg 3 times daily for 1 wk; then 200 mg/d started < 8-10 d after AMI
versus
placebo
patients with AMI - Absence of VF or VT > 3 beatsdouble blind
Follow-up duration: 6·42 mo
ezetimibe versus control
IMPROVE-IT, 2014
NCT00202878
10 mg/day of ezetimibe and 40 mg/day of simvastatin
versus
simvastatin 40 mg/day
subjects with stabilized high-risk acute coronary syndrome double blind
Follow-up duration: 5.68 years
39 countries
gemfibrozil versus placebo
VA-HIT, 1999
NCT00283335
gemfibrozil 1.2g daily
versus
placebo
men with coronary heart disease, an HDL cholesterol level of 40 mg per deciliter (1.0 mmol per liter) or less, and an LDL cholesterol level of 140 mg per deciliter (3.6 mmol per liter) or lessdouble blind
Follow-up duration: 5.1 years
USA
low fat diet versus mediterranean-style diet
Tuttle, 2008
low-fat
versus
Mediterranean-style diets
First MI survivorsopen
Follow-up duration: 24 months
moricizine versus placebo
CAST II (early treatment), 1992
moricizine for 14 days
versus
placebo
acute myocardial infarction double blind
Follow-up duration: 14 days
CAST II (late treatment), 1992
long term moricizine
versus
placebo
patient survivor to a myocardial infarctionwhose ventricular premature depolarizations were adequately suppressed by moricizine double blind
nifedipine versus placebo
SPRINT II, 1993
Nifedipine 20mgx3 started within 3hr of hopsital admission for 6 months
versus
placebo
men and women with suspected acute MIDouble blind
Follow-up duration: 6 months
Israel
SPRINT I, 1988
Nifedipine 10mgx3
versus
placebo
patient surviving MI 7 and 21 days after admissionDouble blind
Follow-up duration: 1 year
Israel
omega-3 Fatty acids versus control
OMEGA, 2009
NCT00251134
omega-3 fatty acids 1g daily (and standard medical therapy)
versus
standard medical therapy alone
Patients within 3-14 days after a non-ST-elevation myocardial infarction (NSTEMI) or ST-elevation myocardial infarction (STEMI)open
Follow-up duration: 1 year
Germany
phenprocoumon versus aspirin
German-Austrian Study Group (oac vs asp), 1980
phenprocoumon
versus
aspirin 1.5 g daily
patients who had survived a myocardial infarction for 30-42 daysdouble blind
Follow-up duration: 2 years
phenprocoumon versus placebo
German-Austrian Study Group (oac vs pbo), 1980
phenprocoumon
versus
placebo
patients who had survived a myocardial infarction for 30-42 daysdouble blind
Follow-up duration: 2 years
pravastatin versus placebo
CARE, 1996
pravastatin 40 mg/d
versus
placebo
men and women with myocardial infarction who had plasma totalcholesterol levels below 240 mg per deciliter (mean,209) and low-density lipoprotein (LDL) cholesterollevels of 115 to 174 mg per deciliterdouble blind
Follow-up duration: 5 years
USA, Canada
LIPID, 1998
pravastatin 40 mg/d
versus
placebo
patients with previous myocardial infarction or unstable angina and a baseline plasma cholesterol concentration of 4.0-7.0 mmol/Ldouble blind
Follow-up duration: 6.1 years
Australie et Nouvelle Zélande
PACT, 2004
pravastatin initiated within 24 hours of onset of synmptoms and for 4 weeks
versus
placebo
patients with unstable angina, non-ST-segment elevation myocardial infarction, or ST-segment elevation myocardial infarction <24 hoursdouble blind
Follow-up duration: 30 days
simvastatin versus placebo
4S, 1994
simvastatin 20 or 40 mg/d, target CT between 3 et 5.2 mmol/l
versus
placebo
patients with angina pectoris or previous myocardial infarction and serum cholesterol 5.5-8.0 mmol/L on a lipid-lowering diet double blind
Follow-up duration: 5.4 years
Scandinavia
succinobucol versus placebo
ARISE, 2007
NCT00066898
succinobucol (300 mg/day)
versus
placebo
high-risk patients with recent acute coronary syndrome Double blind
Follow-up duration: 24 months mean
canada, US, UK, South Africa
ticagrelor versus placebo (on top aspirin)
PEGASUS 60mg, 2015
NCT01225562
ticagrelor at a dose of 60 mg twice daily
versus
placebo
patients who had had a myocardial infarction 1 to 3 years earlierdouble-blind
Follow-up duration: 2.75 y (median)
PEGASUS 90mg, 2015
NCT01225562
ticagrelor at a dose of 90 mg twice daily
versus
patients who had had a myocardial infarction 1 to 3 years earlier double-blind
Follow-up duration: 2.75 y (median)
verapamil versus placebo
DAVIT I, 1984
verapamil 120mgx3
versus
placebo
Double blind
Follow-up duration: 6 months
Danish
DAVIT II, 1990
verapamil 120mgx3 for 18 months
versus
placebo
patients <76years with diagnosis of acute MIDouble blind
Follow-up duration: 16 months
Danish
CRIS, 1996
verapamil retard 360 mg daily
versus
placebo
patients admitted for acute myocardial infarctionDouble blind
Follow-up duration: 23.5 months
Italy
Danish study, 1984
verapamil 0.1mg/kg IV plus 3x120mg orally
versus
placebo
patients under 75 years of age admitted to the CCU with a suspicion of acute myocardial infarction double blind
Follow-up duration: 12 months
Danish
vorapaxar versus placebo (on top aspirin)
TRA-2P TIMI 50, 2012
NCT00526474
vorapaxar (SCH 530348) 2.5-mg daily
versus
placebo (added to the existing standard of care for preventing heart attack and stroke (eg, aspirin, clopidogrel)
patients with a known history of atherosclerosis (MI, ischemic stroke, or peripheral vascular disease)double-blind
Follow-up duration: 2.5 y (median)
warfarin versus aspirin
WARIS II (warfarin alone), 2002
warfarin target INR 2.8-4.2
versus
ASA 160mg/d
patients hospitalized for acute myocardial infarction NA
Follow-up duration: 48 months
Norway
warfarin versus control (on top of aspirin)
WARIS, 1999
warfarin 2.8–4.8
versus
placebo
survivors of acute myocardial infarction double blind
Follow-up duration: 37 months
APRICOT-2, 2002
moderate-intensity coumarin target INR 2-3 (+aspirin)
versus
aspirin
Acute MI after thrombolytics open
Follow-up duration: 3 months
the Netherlands
CARS (warafrin 3mg), 1997
warfarin fixed dose 3mg/d + 80 mg ASA
versus
aspirin 160 mg/d
AMI double blind
Follow-up duration: 14 months
North America
CARS (warfarin 1mg), 1997
warfarin 1mg/d + aspirin 80mg/d
versus
aspirin 160 mg/d
patients who had had myocardial infarctiondouble blind
Follow-up duration: 14 months
North America
CHAMP, 2002
warfarin target INR 1.5-2.5 + aspirin 81 mg daily
versus
aspirin 162 mg/d
AMI (patients enrolled within 14 days of infarction)open
Follow-up duration: 2.7 years
US
LoWASA, 2004
warfarin fixed dose 1.25mg/d + ASA 75mg/d
versus
aspirin alone
AMIopen
Follow-up duration: 5 years
Sweden
WARIS II (warfarin+ASA), 2002
warfarin target INR 2-2.5 +ASA 75mg/d
versus
ASA 160mg/d
patients hospitalized for acute myocardial infarctionopen
Follow-up duration: 4 years
Norway
Zibaeenezhad, 2004
Warfarin target INR 2–3 +aspirin
versus
aspirin 100 mg/day
Acute MIopen
Follow-up duration: 1 year
warfarin versus placebo (on top of aspirin)
Williams, 1997
warfarin target INR 2–2.5 +aspirin
versus
placebo +aspirin
Acute MI, unstable angina double blind
Follow-up duration: 2.5 months